Key facts
- This page summarizes David E. Cohen's Form 3 filing for Evommune, Inc..
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 05 Nov 2025, 20:02.
David E. Cohen - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc.
- Reporting relationship
- Director
- Issuer ticker
- EVMN on NYSE
- Reported as of
- 05 Nov 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 05 Nov 2025, 20:02:55 UTC
- Prior SEC filing
- 18 Apr 2023
- Next SEC filing
- 12 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gregory S. Moss, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David E. Cohen filed Form 3 for Evommune, Inc. on 05 Nov 2025.
Change
- Previous filing in this sequence was filed on 18 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001347383
Primary reporting owner
Cohen David E
- Relationship
- Director
- Address
- C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO
- Signature
- /s/ Gregory S. Moss, Attorney-in-Fact
- Signature date
- 05 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVMN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 17,609
- Date
- 05 Nov 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVMN
holding
Derivative
Series Seed Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 05 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,056
- Exercise price
- Footnotes
- F1
EVMN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 05 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 61,356
- Exercise price
- $3.07
- Footnotes
- F2
EVMN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 05 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,869
- Exercise price
- $3.84
- Footnotes
- F3
EVMN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 05 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,869
- Exercise price
- $1.71
- Footnotes
- F4
EVMN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 05 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,739
- Exercise price
- $2.99
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering, all shares of Series Seed Preferred Stock will be converted into shares of Common Stock of the Issuer.
Footnote F2
One fourth (1/4) of the shares subject to the option award vested on May 11, 2023 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F3
One fourth (1/4) of the shares subject to the option award vested on May 12, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F4
One fourth (1/4) of the shares subject to the option award vested on January 6, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F5
One fourth (1/4) of the shares subject to the option award shall vest on December 17, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.